Ergotamine tartrate (sublingual tablet): Difference between revisions

Ergotamine tartrate (sublingual tablet)
Clinical data
Routes of; administration	Oral
ATC code	N02CA02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Metabolism	hepatic
Excretion	renal
Identifiers
	IUPAC name Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)- (9CI);
CAS Number	113-15-5;
PubChem CID	9787;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C33H35N5O5
Molar mass	581.66 g/mol

VisualWikitext

Revision as of 01:51, 11 February 2014

Ergotamine
ERGOMAR (ergotamine tartrate) tablet^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Medihaler ergotamine (ergotamine tartrate) aerosol, metered^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Medihaler ergotamine (ergotamine tartrate) aerosol, metered
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

For patient information about Ergotamine, click here.

Synonyms / Brand Names:

Overview

Ergotamine is an ergopeptine and part of the ergot family of alkaloids; it is structurally and biochemically closely related to ergoline. It possesses structural similarity to several neurotransmitters, and has biological activity as a vasoconstrictor. It is used medicinally for migraine prevention (sometimes in combination with caffeine), and to induce childbirth and prevent post-partum haemorrhage.

FDA Package Insert

Mechanism of action

The mechanism of action of ergotamine is complex. The molecule shares similarity with neurotransmitters such as serotonin, dopamine, and adrenaline and can thus bind to several cell receptors acting both as agonist and antagonist in signal transduction within cellular tissues. The anti-migraine effect is due to constriction of the intercranial extracerebral blood vessels through the 5-HT_1B receptor, and by inhibiting trigeminal neurotransmission by 5-HT_1D receptors. Ergotamine also has effects on the dopamine and noradrenaline receptors. It is its action on the D2 dopamine and 5-HT_1A receptors that can cause some side effects. ^[1]

Biosynthesis

Ergotamine is a secondary metabolite (natural product) and the principal alkaloid produced by the ergot fungus, Claviceps purpurea, and related fungi in the family Clavicipitaceae. Its biosynthesis in these fungi requires the amino acid, L-tryptophan, and dimethylallyl diphosphate. These precursor compounds are the substrates for the enzyme, dimethylally-tryptophan (DMAT) synthase, catalyzing the first step in ergot alkaloid biosynthesis, i.e., the prenylation of L-tryptophan. Further reactions, involving methyltransferase and oxygenase enzymes, yield the ergoline, lysergic acid. Lysergic acid (LA) is the substrate of lysergyl peptide synthetase, a nonribosomal peptide synthetase, which covalently links LA to the amino acids, L-alanine, L-proline, and L-phenylalanine. Enzyme-catalyzed or spontaneous cyclizations, oxygenations/oxidations, and isomerizations at selected residues precede, and give rise to, formation of ergotamine.^[2]

Illegal uses

Ergotamine is also a precursor of LSD, lysergic acid diethylamide.

References

↑ Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ (2000). "Ergotamine in the acute treatment of migraine: a review and European consensus". Brain. 123: 9–18. PMID 10611116.
↑ Schardl CL, Panaccione DG, Tudzynski P (2006). "Ergot alkaloids--biology and molecular biology". Alkaloids Chem. Biol. 63: 45–86. PMID 17133714.

Template:Antimigraine preparations

da:Ergotamin de:Ergotamin nl:Ergotamine sv:Ergotamin

Template:WikiDoc Sources

[Tfelt-1] Tfelt-Hansen P, Saxena PR, Dahlof C, Pascual J, Lainez M, Henry P, Diener H, Schoenen J, Ferrari MD, Goadsby PJ (2000). "Ergotamine in the acute treatment of migraine: a review and European consensus". Brain. 123: 9–18. PMID 10611116.

[Schardl-2] Schardl CL, Panaccione DG, Tudzynski P (2006). "Ergot alkaloids--biology and molecular biology". Alkaloids Chem. Biol. 63: 45–86. PMID 17133714.

[1]

[2]

@@ Line 1: / Line 1: @@
+__NOTOC__
+{{Ergotamine}}
+{{CMG}}; {{AE}}
+'''''For patient information about Ergotamine, click [[Ergotamine (patient information)|here]].'''''
+{{SB}}
+==Overview==
 {{drugbox |
 | image = Ergotamine.png
 | IUPAC_name = Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'-alpha)- (9CI)
 | CAS_number = 113-15-5
 | ATC_prefix = N02
 | ATC_suffix = CA02
 | C=33 | H=35| N=5| O=5
@@ Line 10: / Line 19: @@
 | metabolism = hepatic
 | excretion = renal
 | pregnancy_category =
 | PubChem=9787
 | pregnancy_AU =
@@ Line 20: / Line 29: @@
 | routes_of_administration = [[Wiktionary:oral|Oral]]
 }}
 '''Ergotamine''' is an [[ergopeptine]] and part of the [[ergot]] family of [[alkaloid]]s; it is structurally and biochemically closely related to [[ergoline]]. It possesses structural similarity to several [[neurotransmitter]]s, and has [[biological activity]] as a [[vasoconstrictor]]. It is used [[Pharmacology|medicinally]] for [[migraine]] prevention (sometimes in combination with [[caffeine]]), and to induce [[childbirth]] and prevent [[post-partum]] [[haemorrhage]].
+==Category==
+Anti Migraine Drugs
+==FDA Package Insert==
+'''  [[Ergotamine indications and usage|Indications and Usage]]'''
+'''| [[Ergotamine dosage and administration|Dosage and Administration]]'''
+'''| [[Ergotamine dosage forms and strengths|Dosage Forms and Strengths]]'''
+'''| [[Ergotamine contraindications|Contraindications]]'''
+'''| [[Ergotamine warnings and precautions|Warnings and Precautions]]'''
+'''| [[Ergotamine adverse reactions|Adverse Reactions]]'''
+'''| [[Ergotamine drug interactions|Drug Interactions]]'''
+'''| [[Ergotamine use in specific populations|Use in Specific Populations]]'''
+'''| [[Ergotamine overdosage|Overdosage]]'''
+'''| [[Ergotamine description|Description]]'''
+'''| [[Ergotamine clinical pharmacology|Clinical Pharmacology]]'''
+'''| [[Ergotamine nonclinical toxicology|Nonclinical Toxicology]]'''
+'''| [[Ergotamine clinical studies|Clinical Studies]]'''
+'''| [[Ergotamine how supplied storage and handling|How Supplied/Storage and Handling]]'''
+'''| [[Ergotamine patient counseling information|Patient Counseling Information]]'''
+'''| [[Ergotamine labels and packages|Labels and Packages]]'''
 ==Mechanism of action==